223 related articles for article (PubMed ID: 24973208)
1. Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis.
Rizvi S; Mertens JC; Bronk SF; Hirsova P; Dai H; Roberts LR; Kaufmann SH; Gores GJ
J Biol Chem; 2014 Aug; 289(33):22835-22849. PubMed ID: 24973208
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma.
Mertens JC; Fingas CD; Christensen JD; Smoot RL; Bronk SF; Werneburg NW; Gustafson MP; Dietz AB; Roberts LR; Sirica AE; Gores GJ
Cancer Res; 2013 Jan; 73(2):897-907. PubMed ID: 23221385
[TBL] [Abstract][Full Text] [Related]
3. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.
Cadamuro M; Brivio S; Mertens J; Vismara M; Moncsek A; Milani C; Fingas C; Cristina Malerba M; Nardo G; Dall'Olmo L; Milani E; Mariotti V; Stecca T; Massani M; Spirli C; Fiorotto R; Indraccolo S; Strazzabosco M; Fabris L
J Hepatol; 2019 Apr; 70(4):700-709. PubMed ID: 30553841
[TBL] [Abstract][Full Text] [Related]
4. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis.
Lagares D; Santos A; Grasberger PE; Liu F; Probst CK; Rahimi RA; Sakai N; Kuehl T; Ryan J; Bhola P; Montero J; Kapoor M; Baron M; Varelas X; Tschumperlin DJ; Letai A; Tager AM
Sci Transl Med; 2017 Dec; 9(420):. PubMed ID: 29237758
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
6. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma.
Cadamuro M; Nardo G; Indraccolo S; Dall'olmo L; Sambado L; Moserle L; Franceschet I; Colledan M; Massani M; Stecca T; Bassi N; Morton S; Spirli C; Fiorotto R; Fabris L; Strazzabosco M
Hepatology; 2013 Sep; 58(3):1042-53. PubMed ID: 23505219
[TBL] [Abstract][Full Text] [Related]
7. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
Ewald L; Dittmann J; Vogler M; Fulda S
Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
[TBL] [Abstract][Full Text] [Related]
8. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
Huang S; Sinicrope FA
Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764
[TBL] [Abstract][Full Text] [Related]
9. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
[TBL] [Abstract][Full Text] [Related]
10. Targeting PDGFR-β in Cholangiocarcinoma.
Fingas CD; Mertens JC; Razumilava N; Bronk SF; Sirica AE; Gores GJ
Liver Int; 2012 Mar; 32(3):400-9. PubMed ID: 22133064
[TBL] [Abstract][Full Text] [Related]
11. BH3 mimetics inhibit growth of chondrosarcoma--a novel targeted-therapy for candidate models.
Morii T; Ohtsuka K; Ohnishi H; Mochizuki K; Yoshiyama A; Aoyagi T; Hornicek FJ; Ichimura S
Anticancer Res; 2014 Nov; 34(11):6423-30. PubMed ID: 25368242
[TBL] [Abstract][Full Text] [Related]
12. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
Zhang J; Huang K; O'Neill KL; Pang X; Luo X
Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
[TBL] [Abstract][Full Text] [Related]
13. Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells.
Dai H; Ding H; Meng XW; Peterson KL; Schneider PA; Karp JE; Kaufmann SH
Genes Dev; 2015 Oct; 29(20):2140-52. PubMed ID: 26494789
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.
Song T; Chai G; Liu Y; Yu X; Wang Z; Zhang Z
Br J Pharmacol; 2016 Feb; 173(3):471-83. PubMed ID: 26493374
[TBL] [Abstract][Full Text] [Related]
15. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
Kazi A; Sun J; Doi K; Sung SS; Takahashi Y; Yin H; Rodriguez JM; Becerril J; Berndt N; Hamilton AD; Wang HG; Sebti SM
J Biol Chem; 2011 Mar; 286(11):9382-92. PubMed ID: 21148306
[TBL] [Abstract][Full Text] [Related]
16. Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer.
Potter DS; Du R; Bhola P; Bueno R; Letai A
Cell Death Dis; 2021 Jul; 12(8):741. PubMed ID: 34315868
[TBL] [Abstract][Full Text] [Related]
17. S1, a novel pan-BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak.
Song T; Chang X; Zhang Z; Liu Y; Shen X
J Pharmacol Sci; 2012; 119(4):330-40. PubMed ID: 22814102
[TBL] [Abstract][Full Text] [Related]
18. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.
Vandenberg CJ; Cory S
Blood; 2013 Mar; 121(12):2285-8. PubMed ID: 23341542
[TBL] [Abstract][Full Text] [Related]
19. BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis.
Heinicke U; Haydn T; Kehr S; Vogler M; Fulda S
Oncogene; 2018 Sep; 37(39):5325-5339. PubMed ID: 29858601
[TBL] [Abstract][Full Text] [Related]
20. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Besbes S; Pocard M; Mirshahi M; Billard C
Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]